JOT Automation and Tensor ID Work on Syringe Inspection Platform - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

JOT Automation and Tensor ID Work on Syringe Inspection Platform



JOT Automation, a supplier of test and production solutions, and Tensor ID, specialists in machine vision solutions, will highlight the benefits of the companies' combined service and technology offering at ATX West as the companies exhibit together for the first time. The companies have started to codevelop a fully automated solution for the quality assurance of auto-injector syringes.

"Together we are pre-promoting an auto injection syringe inspection platform. The vision-based platform enables inspection of silicone coating inside glass syringes,” said Jorma Venäläinen, business line director of Life Sciences at JOT Automation, in the press release.

“The quality of silicone oil and its distribution on the inner syringe surface are two important factors that affect the injection performance of auto-injector devices. To better identify and screen out syringes with insufficient or non-uniform silicone oil distribution, our new technology visualizes, quantifies, and analyzes silicone oil distribution.”

"The market for auto-injectors is set to rise to 1.07 billion dollars by 2015," said Stacey Swall from Tensor ID in the press release. "In addition we see possibilities to exploit this technology for quality inspection of pipettes, vials and tubes.”

Source: JOT Automation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here